NCT06547528 - A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

January 31, 2029

Study Completion Date

April 30, 2029

Conditions

Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG

ONO-4685

ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.

Trial Locations (14)

Unknown

RECRUITING

Aichi Cancer Center Hospital, Nagoya

RECRUITING

Nagoya University Hospital, Nagoya

RECRUITING

Akita University Hospital, Akita

RECRUITING

National Cancer Center Hospital East, Kashiwa-shi

RECRUITING

Kyushu University Hospital, Fukuoka

RECRUITING

Hokkaido University Hospital, Sapporo

RECRUITING

Tokai University Hospital, Isehara-shi

RECRUITING

Kumamoto University Hospital, Kumamoto

RECRUITING

University Hospital Kyoto Prefectural University of Medicine, Kyoto

RECRUITING

Tohoku University Hospital, Sendai

RECRUITING

Okayama University Hospital, Okayama

RECRUITING

Kindai University Hospital, Osaka Sayama-shi

NOT_YET_RECRUITING

Osaka University Hospital, Osaka-fu

RECRUITING

Cancer Institute Hospital of JFCR, Koto-ku